United Therapeutics Corporation
UTHR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $1,195,100 | $984,800 | $727,300 | $475,800 |
| Dep. & Amort. | $72,500 | $53,200 | $51,300 | $49,900 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $144,000 | $39,100 | $106,800 | $138,500 |
| Change in WC | -$60,200 | -$97,800 | -$141,200 | -$174,200 |
| Other Non-Cash | -$24,300 | -$1,300 | $58,300 | $108,200 |
| Operating Cash Flow | $1,327,100 | $978,000 | $802,500 | $598,200 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$246,500 | -$230,400 | -$138,800 | -$120,800 |
| Net Acquisitions | -$30,500 | -$89,200 | -$1,500 | $0 |
| Inv. Purchases | -$1,646,100 | -$2,514,300 | -$1,708,600 | -$1,895,300 |
| Inv. Sales/Matur. | $2,368,800 | $2,137,300 | $1,033,900 | $1,529,200 |
| Other Inv. Act. | -$28,500 | -$23,000 | $3,500 | $0 |
| Investing Cash Flow | $417,200 | -$719,600 | -$811,500 | -$486,900 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$400,000 | -$100,000 | $0 | $0 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$1,012,200 | -$13,800 | -$11,400 | -$10,800 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $157,400 | $101,900 | $86,800 | $55,600 |
| Financing Cash Flow | -$1,254,800 | -$11,900 | $75,400 | $44,800 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $489,500 | $246,500 | $66,400 | $156,100 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $1,207,700 | $961,200 | $894,800 | $738,700 |
| End Cash | $1,697,200 | $1,207,700 | $961,200 | $894,800 |
| Free Cash Flow | $1,080,600 | $747,600 | $663,700 | $477,400 |